46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
May 31, 2026
|
16:00
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
...
Full Story at Source
Related News
CPKC to maintain rail operations across Canada during IBEW strike
Here's how Gap's yoga-wear maker Athleta went from must-have to 'generic'
'I have no preexisting conditions': I'm 56, earn $198,000 and want to retire early. Can I afford private healthcare?
Daraxonrasib vs. pancreatic cancer: Experimental pill helped people live longer
